ethyl 3,7-dimethyl-6-(phenylsulfonylmethyl)-9-cyano-1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazine-5-carboxylate | 958450-12-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: ethyl 3,7-dimethyl-6-(phenylsulfonylmethyl)-9-cyano-1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazine-5-carboxylate
• 英文别名: Ethyl 5-cyano-2,7-dimethyl-8-(phenylsulfanylmethyl)-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate
• CAS: 958450-12-9
• 化学式: C₂₃H₂₃N₃O₃S
• 分子量: 421.52
• InChiKey: NZEKJJXHJHQAHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  92.8
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  糠醛 、 聚合甲醛 、 正戊醛 、 Ethyl 6-bromo-5-hydroxy-1-methyl-2-[(2-methylimidazol-1-yl)methyl]indole-3-carboxylate 、 Ethyl 6-bromo-5-hydroxy-2-[[2-hydroxyethyl(methyl)amino]methyl]-1-methylindole-3-carboxylate 、 6-Bromo-5-hydroxy-1-methyl-2-[(pyridin-4-ylamino)methyl]-3-indolecarboxylic acid ethyl ester 、 ethyl-6-bromo-2-((dimethylamino)methyl)-5-hydroxy-1-phenyl-1H-indole-3-carboxylate 、 、 Ethyl 5-hydroxy-2-[(4-methylpiperazino)methyl]-1-phenyl-1H-indole-3-carboxylate 、 Ethyl 5-hydroxy-1-methyl-6-(3-pyridyl)-2-(1-pyrrolidinylmethyl)-1H-indole-3-carboxylate 、 、 、 、 、 、 、 、 ethyl 1-benzyl-6-bromo-5-hydroxy-2-[(2-methylpiperidin-1-yl)methyl]-1H-indole-3-carboxylate 、 ethyl 1-benzyl-6-bromo-5-hydroxy-2-[(4-methylpiperidin-1-yl)methyl]-1H-indole-3-carboxylate 、 ethyl 1-benzyl-6-bromo-5-hydroxy-2-(piperidin-1-ylmethyl)-1H-indole-3-carboxylate 、 ethyl 6-bromo-1-cyclohexyl-5-hydroxy-2-[(4-phenylpiperazin-1-yl)methyl]-1H-indole-3-carboxylate 、 苯甲醛 、 6-Bromo-5-hydroxy-1-methyl-2-phenylaminomethyl-1H-indole-3-carboxylic acid ethyl ester 、 甲胺 、 苄胺 以 1,4-二氧六环 为溶剂， 反应 48.0h， 生成 Ethyl 5-bromo-2,7-dimethyl-8-[(2-methylimidazol-1-yl)methyl]-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 5-bromo-2,7-dimethyl-8-(phenoxymethyl)-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 ethyl 3,7-dimethyl-6-(phenylsulfonylmethyl)-9-cyano-1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazine-5-carboxylate 、 Ethyl 5-bromo-8-[[2-hydroxyethyl(methyl)amino]methyl]-2,7-dimethyl-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 2,7-dimethyl-8-(methylaminomethyl)-5-pyridin-3-yl-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 ethyl 9-bromo-3,7-dimethyl-6-((phenylamino)methyl)-1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazine-5-carboxylate 、 ethyl 9-bromo-3,7-dimethyl-6-((pyridin-4-yl)methyl)-1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazine-5-carboxylate 、 ethyl 9-bromo-6-((dimethylamino)methyl)-3-methyl-7-phenyl-1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazine-5-carboxylate 、 Ethyl 5-bromo-2,7-dimethyl-8-[(4-methylanilino)methyl]-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 8-(anilinomethyl)-5-bromo-3-(furan-2-yl)-2,7-dimethyl-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 2-methyl-8-[(4-methylpiperazin-1-yl)methyl]-7-phenyl-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 5-bromo-2,7-dimethyl-3-phenyl-8-(phenylsulfanylmethyl)-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 2-benzyl-5-bromo-7-methyl-8-(phenylsulfanylmethyl)-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 2,7-dimethyl-5-(pyridin-3-YL)-8-[(pyrrolidin-1-YL)methyl]-1H,2H,3H,7H-[1,3]oxazino[5,6-E]indole-9-carboxylate 、 ethyl 3,7-dimethyl-9-(pyridin-4-yl)-6-(phenylsulfonylmethyl)-1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazine-5-carboxylate 、 Ethyl 5-bromo-8-[(2-cyano-5-methylphenyl)sulfanylmethyl]-2,7-dimethyl-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Benzyl 5-bromo-2,7-dimethyl-8-(morpholin-4-ylmethyl)-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 5-bromo-8-[[4-(cyanomethyl)piperazin-1-yl]methyl]-2,7-dimethyl-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Cyclohexyl 8-(anilinomethyl)-5-bromo-2,7-dimethyl-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 5-bromo-8-[[4-(2-hydroxyethyl)piperazin-1-yl]methyl]-2,7-dimethyl-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 7-benzyl-5-bromo-2-methyl-8-[(2-methylpiperidin-1-yl)methyl]-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 7-benzyl-5-bromo-2-methyl-8-[(4-methylpiperidin-1-yl)methyl]-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 Ethyl 7-benzyl-5-bromo-2-methyl-8-(piperidin-1-ylmethyl)-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate 、 ethyl 7-benzyl-9-bromo-3-methyl-6-((1-methylpiperazin-4-yl)methyl)-1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazine-5-carboxylate 、 Ethyl 5-bromo-7-cyclohexyl-2-methyl-8-[(4-phenylpiperazin-1-yl)methyl]-1,3-dihydropyrrolo[3,2-f][1,3]benzoxazine-9-carboxylate
  参考文献：
  名称：

  EP2036889

  摘要：

  公开号：

文献信息

• SUBSTITUTED INDOLES AND A METHOD FOR THE PRODUCTION AND USE THEREOF
  申请人：Alla Chem, LLC.

  公开号：EP2036889A2

  公开（公告）日：2009-03-18

  The invention relates to novel substituted indoles, to the use thereof in the form of pharmacological composition substances and to use of said compositions for the manufacture of medicinal preparations used for preventing and treating viral diseases, in particular caused by viruses of infectious hepatitis (HCV, HBV), human immune deficiency (HIV), atypical pneumonia (SARS) and bird flu. The invention proposes novel substituted indoles of general formula (I) or racemates, optical isomers, pharmaceutically acceptable salts and/or hydrates thereof, wherein R1, R14 and R24 independently are an aminogroup substituent selected from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl, or R14 and R24 together with the nitrogen atom to which they are attached, form via R14 and R24 an optionally substituted azaheterocyclyl or guanidyl; R2 is an alkyl substituent selected from hydrogen, an optionally substituted mercaptogroup, optionally substituted aminogroup and optionally substituted hydroxyl; R3 is lower alkyl, R5 is an hydrogen atom or R5 together with the oxygen atom to which it is attached and R24 together with the nitrogen atom to which it is attached close, via R5 and R24 an oxazine ring; R6 is a cyclic system substituent selected from hydrogen, halogen atom, cyanogroup, optionally substituted aryl or substituted heterocyclyl.

  本发明涉及新型取代的吲哚，以药理组合物的形式使用它们，以及使用所述组合物制造用于预防和治疗病毒性疾病的药物制剂，特别是由传染性肝炎（HCV、HBV）、人类免疫缺陷（HIV）、非典型肺炎（SARS）和禽流感病毒引起的疾病。本发明提出了通式（I）的新型取代吲哚或其外消旋体、光学异构体、药学上可接受的盐和/或水合物，其中 R1、R14 和 R24 独立地为选自氢、任选取代的烷基、任选取代的环烷基、任选取代的芳基或任选取代的杂环基的氨基取代基，或 R14 和 R24 与它们所连接的氮原子一起通过 R14 和 R24 形成任选取代的杂杂环基或胍基；R2 是烷基取代基，选自氢、任选取代的巯基、任选取代的氨基和任选取代的羟基；R3 是低级烷基，R5 是氢原子或 R5 与所连接的氧原子和 R24 与所连接的氮原子一起通过 R5 和 R24 形成恶嗪环；R6 是环状系统取代基，选自氢、卤素原子、氰基、任选取代的芳基或取代的杂环基。
• Substituted Indoles and a Method for the Production and Use Thereof
  申请人：Ivashchenko Andrey Alexandrovich

  公开号：US20110160197A1

  公开（公告）日：2011-06-30

  The invention relates to novel substituted indoles, to the use thereof in the form of pharmacological composition substances and to use of said composition for producing medicinal preparations used for preventing and treating viral diseases, in particular caused by viruses of infectious hepatitis (HCV, HBV), human immune deficiency (HIV), atypical pneumonia (SARS) and bird flu. The invention proposes novel substituted indoles of general formula (1) or the racemates or the optical isomers or the pharmaceutically acceptable salts and/or hydrates thereof, wherein R 1 , R 1 4 and R 2 4 independently of each other are an aminogroup substituent selected for hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl or optionally substituted heterocyclyl, or R 1 4 and R 2 4 together with a nitrogen atom, with which they are bound, form through R 1 4 and R 2 4 optionally substituted azaheterocyclyl or guanidyl; R 2 is analkyl substituent selected from hydrogen, an optionally substituted mercaptogroup, optionally substituted aminogroup and optionally substituted hydroxyl; R 3 is lower alkyl, R 5 is an hydrogen atom or R 5 together with an oxygen atom with which it is linked or R 2 4 together with a nitrogen atom with which it is linked close, via R 5 and R 2 4 an oxazine cycle; R 6 is a cyclic system substituent selected for hydrogen, a halogen atom, cyanogroup, optionally substituted aryl or substituted heterocyclyl.
• US8329689B2
  申请人：——

  公开号：US8329689B2

  公开（公告）日：2012-12-11
• EP2036889
  申请人：——

  公开号：——

  公开（公告）日：——